Kriya Therapeutics is a fully integrated platform company pioneering novel technologies and therapeutics in gene therapy.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
07/23/2023 | Series C-1 | $60.14MM | $xx.xx | $914.46MM | Patient Square Capital, Bluebird Ventures, CAM Capital, Dexcel Pharma, Foresite Capital, JDRF T1D Fund, Lightswitch Capital, Narya Capital, QVT, Transhuman Capital | |
Price per Share
$xx.xx
Shares Outstanding
8,312,005
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Patient Square Capital, Bluebird Ventures, CAM Capital, Dexcel Pharma, Foresite Capital, JDRF T1D Fund, Lightswitch Capital, Narya Capital, QVT, Transhuman Capital
|
||||||
05/16/2022 | Series C | $369.86MM | $xx.xx | $768.28MM | Patient Square Capital, Bluebird Ventures, CAM Capital, Dexcel Pharma, Foresite Capital, JDRF T1D Fund, Lightswitch Capital, Narya Capital, QVT, Transhuman Capital | |
Price per Share
$xx.xx
Shares Outstanding
51,119,663
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Patient Square Capital, Bluebird Ventures, CAM Capital, Dexcel Pharma, Foresite Capital, JDRF T1D Fund, Lightswitch Capital, Narya Capital, QVT, Transhuman Capital
|
||||||
07/14/2021 | Series B | $100MM | $xx.xx | $319.24MM | Patient Square Capital, Woodline Partners LP, CAM Capital, Hongkou, Alumni Ventures, QVT, Dexcel Pharma, Foresite Capital, Bluebird Ventures, Transhuman Capital, Narya Capital, Amplo, JDRF T1D Fund | |
Price per Share
$xx.xx
Shares Outstanding
16,585,673
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Patient Square Capital, Woodline Partners LP, CAM Capital, Hongkou, Alumni Ventures, QVT, Dexcel Pharma, Foresite Capital, Bluebird Ventures, Transhuman Capital, Narya Capital, Amplo, JDRF T1D Fund
|
||||||
05/12/2020 | Series A-2 | $5.13MM | $xx.xx | $197.6MM | QVT, Dexcel Pharma, Foresite Capital, Bluebird Ventures, Narya Capital, Amplo, Paul Manning, Asia Alpha, Transhuman Capital | |
Price per Share
$xx.xx
Shares Outstanding
1,291,381
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
QVT, Dexcel Pharma, Foresite Capital, Bluebird Ventures, Narya Capital, Amplo, Paul Manning, Asia Alpha, Transhuman Capital
|
||||||
05/12/2020 | Series A-1 | $82.5MM | $xx.xx | $197.6MM | QVT, Dexcel Pharma, Foresite Capital, Bluebird Ventures, Narya Capital, Amplo, Paul Manning, Asia Alpha, Transhuman Capital | |
Price per Share
$xx.xx
Shares Outstanding
16,598,254
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
QVT, Dexcel Pharma, Foresite Capital, Bluebird Ventures, Narya Capital, Amplo, Paul Manning, Asia Alpha, Transhuman Capital
|